DK3819007T3 - Doseringsplan for anti-bcma-midler - Google Patents

Doseringsplan for anti-bcma-midler Download PDF

Info

Publication number
DK3819007T3
DK3819007T3 DK19208417.6T DK19208417T DK3819007T3 DK 3819007 T3 DK3819007 T3 DK 3819007T3 DK 19208417 T DK19208417 T DK 19208417T DK 3819007 T3 DK3819007 T3 DK 3819007T3
Authority
DK
Denmark
Prior art keywords
bcma
agents
dosage schedule
schedule
dosage
Prior art date
Application number
DK19208417.6T
Other languages
English (en)
Inventor
Julia Stieglmaier
Birgit Huber
Alexander Minella
Vijay Upreti
Original Assignee
Amgen Res Munich Gmbh
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=68581157&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK3819007(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Amgen Res Munich Gmbh, Amgen Inc filed Critical Amgen Res Munich Gmbh
Application granted granted Critical
Publication of DK3819007T3 publication Critical patent/DK3819007T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
DK19208417.6T 2019-11-11 2019-11-11 Doseringsplan for anti-bcma-midler DK3819007T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP19208417.6A EP3819007B1 (en) 2019-11-11 2019-11-11 Dosing regimen for anti-bcma agents

Publications (1)

Publication Number Publication Date
DK3819007T3 true DK3819007T3 (da) 2024-09-30

Family

ID=68581157

Family Applications (2)

Application Number Title Priority Date Filing Date
DK19208417.6T DK3819007T3 (da) 2019-11-11 2019-11-11 Doseringsplan for anti-bcma-midler
DK20729951.2T DK4058148T5 (da) 2019-11-11 2020-05-08 Doseringsregime for anti-bcma-midler

Family Applications After (1)

Application Number Title Priority Date Filing Date
DK20729951.2T DK4058148T5 (da) 2019-11-11 2020-05-08 Doseringsregime for anti-bcma-midler

Country Status (20)

Country Link
US (1) US20210139584A1 (da)
EP (3) EP3819007B1 (da)
JP (2) JP2022554362A (da)
AU (1) AU2020381671A1 (da)
CA (1) CA3155069A1 (da)
DK (2) DK3819007T3 (da)
ES (2) ES2987783T3 (da)
FI (2) FI3819007T3 (da)
HR (2) HRP20241281T1 (da)
HU (2) HUE068401T2 (da)
LT (2) LT3819007T (da)
MA (1) MA47888B1 (da)
MX (1) MX2022005628A (da)
PL (2) PL3819007T3 (da)
PT (2) PT3819007T (da)
RS (2) RS65943B1 (da)
SI (2) SI3819007T1 (da)
SM (2) SMT202400373T1 (da)
TW (1) TW202118784A (da)
WO (1) WO2021094000A1 (da)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112019012354A2 (pt) 2016-12-21 2019-11-26 Teneobio, Inc. anticorpos apenas de cadeia pesada anti-bcma
TW202233682A (zh) * 2020-11-10 2022-09-01 美商安進公司 用於投與ＢＣＭＡｘＣＤ３結合分子之方法
EP4428156A4 (en) * 2021-12-03 2026-03-04 Shandong Simcere Biopharmaceutical Co., Ltd. ANTI-BCMA NANOBODY AND USE THEREOF

Family Cites Families (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4447A (en) 1846-04-04 Car- wheel
US233A (en) 1837-06-14 Improvement in plows
US4475196A (en) 1981-03-06 1984-10-02 Zor Clair G Instrument for locating faults in aircraft passenger reading light and attendant call control system
US4439196A (en) 1982-03-18 1984-03-27 Merck & Co., Inc. Osmotic drug delivery system
US4447224A (en) 1982-09-20 1984-05-08 Infusaid Corporation Variable flow implantable infusion apparatus
US4487603A (en) 1982-11-26 1984-12-11 Cordis Corporation Implantable microinfusion pump system
US4486194A (en) 1983-06-08 1984-12-04 James Ferrara Therapeutic device for administering medicaments through the skin
US4596556A (en) 1985-03-25 1986-06-24 Bioject, Inc. Hypodermic injection apparatus
US4790824A (en) 1987-06-19 1988-12-13 Bioject, Inc. Non-invasive hypodermic injection device
US4941880A (en) 1987-06-19 1990-07-17 Bioject, Inc. Pre-filled ampule and non-invasive hypodermic injection device assembly
US5064413A (en) 1989-11-09 1991-11-12 Bioject, Inc. Needleless hypodermic injection device
US5312335A (en) 1989-11-09 1994-05-17 Bioject Inc. Needleless hypodermic injection device
GB9206422D0 (en) 1992-03-24 1992-05-06 Bolt Sarah L Antibody preparation
US7381803B1 (en) 1992-03-27 2008-06-03 Pdl Biopharma, Inc. Humanized antibodies against CD3
US5383851A (en) 1992-07-24 1995-01-24 Bioject Inc. Needleless hypodermic injection device
DK1071752T3 (da) 1998-04-21 2003-10-20 Micromet Ag CD19xCD3-specifikke polypeptider og anvendelsen deraf
GB9815909D0 (en) 1998-07-21 1998-09-16 Btg Int Ltd Antibody preparation
AU5728999A (en) 1998-07-28 2000-02-21 Micromet Ag Heterominibodies
JP4948174B2 (ja) 2003-10-16 2012-06-06 マイクロメット アクツィエン ゲゼルシャフト 多重特異的脱免疫ｃｄ３−結合物質
CA2569509C (en) 2004-06-03 2014-08-12 Novimmune S.A. Anti-cd3 antibodies and methods of use thereof
EP1940881B1 (en) 2005-10-11 2016-11-30 Amgen Research (Munich) GmbH Compositions comprising cross-species-specific antibodies and uses thereof
TW200745163A (en) 2006-02-17 2007-12-16 Syntonix Pharmaceuticals Inc Peptides that block the binding of IgG to FcRn
WO2008119567A2 (en) 2007-04-03 2008-10-09 Micromet Ag Cross-species-specific cd3-epsilon binding domain
JP2011516603A (ja) 2008-04-17 2011-05-26 アブリンクス エン．ヴェー． 血清タンパク質と結合することが可能なペプチド、並びにこれを含む化合物、構築物及びポリペプチド
AU2009299794B2 (en) 2008-10-01 2015-08-13 Amgen Research (Munich) Gmbh Cross-species-specific single domain bispecific single chain antibody
BR112012009450A2 (pt) 2009-10-30 2017-05-23 Novozymes Biopharma Dk As variantes de albumina
EP2635598A1 (en) 2010-11-01 2013-09-11 Novozymes Biopharma DK A/S Albumin variants
EP2640750A1 (en) 2010-11-16 2013-09-25 Boehringer Ingelheim International GmbH Agents and methods for treating diseases that correlate with bcma expression
AU2012251583B2 (en) 2011-05-05 2017-06-08 Albumedix Ltd. Albumin variants
PH12013502531A1 (en) 2011-08-23 2014-01-20 Roche Glycart Ag Bispecific t cell activating antigen binding molecules
WO2013026837A1 (en) 2011-08-23 2013-02-28 Roche Glycart Ag Bispecific t cell activating antigen binding molecules
TWI679212B (zh) * 2011-11-15 2019-12-11 美商安進股份有限公司 針對ｂｃｍａ之e3以及ｃｄ３的結合分子
EP2780364A2 (en) 2011-11-18 2014-09-24 Eleven Biotherapeutics, Inc. Proteins with improved half-life and other properties
ES2664328T3 (es) 2012-03-16 2018-04-19 Albumedix A/S Variantes de albúmina
CA2890766A1 (en) 2012-11-08 2014-05-15 Novozymes Biopharma Dk A/S Albumin variants
EP2970484B2 (en) 2013-03-15 2022-09-21 Amgen Inc. Heterodimeric bispecific antibodies
US20140302037A1 (en) 2013-03-15 2014-10-09 Amgen Inc. BISPECIFIC-Fc MOLECULES
US20140308285A1 (en) 2013-03-15 2014-10-16 Amgen Inc. Heterodimeric bispecific antibodies
US20160257748A1 (en) 2013-09-25 2016-09-08 Amgen Inc. V-c-fc-v-c antibody
EP2982692A1 (en) 2014-08-04 2016-02-10 EngMab AG Bispecific antibodies against CD3epsilon and BCMA
PL3988117T3 (pl) 2015-04-13 2025-03-10 Pfizer Inc. Przeciwciała terapeutyczne i ich zastosowania
EA039859B1 (ru) 2015-07-31 2022-03-21 Эмджен Рисерч (Мюник) Гмбх Биспецифические конструкты антител, связывающие egfrviii и cd3
EP3670535A1 (en) 2015-08-03 2020-06-24 EngMab Sàrl Monoclonal antibodies against bcma
TWI811023B (zh) 2015-08-17 2023-08-01 美商健生生物科技公司 抗bcma抗體，結合bcma及cd3之雙特異性抗原結合分子及其用途
IL313507A (en) 2016-02-03 2024-08-01 Amgen Res Munich Gmbh Constructs of bispecific antibodies to BCMA and CD3 that bind to T cells, preparations containing the same and uses thereof
US11124577B2 (en) 2016-11-02 2021-09-21 Engmab Sàrl Bispecific antibody against BCMA and CD3 and an immunological drug for combined use in treating multiple myeloma
JP7084990B2 (ja) 2017-10-13 2022-06-15 ハープーン セラピューティクス，インク． 三重特異性タンパク質と使用方法
EA202092830A1 (ru) 2018-05-23 2021-04-08 Селджин Корпорейшн Антипролиферативные соединения и биспецифические антитела к bcma и cd3 для комбинированного применения
TWI838389B (zh) 2018-07-19 2024-04-11 美商再生元醫藥公司 雙特異性抗-BCMAｘ抗-CD3抗體及其用途
BR112021005669A2 (pt) * 2018-09-28 2021-06-22 Amgen Inc. anticorpos contra bcma solúvel
WO2020150702A1 (en) * 2019-01-18 2020-07-23 University Of Southern California Methods and compositions to improve the safety and efficacy of cellular therapies
AU2020307471A1 (en) 2019-06-24 2022-01-27 Novartis Ag Dosing regimen and combination therapies for multispecific antibodies targeting B-cell maturation antigen
PL3766701T3 (pl) 2019-07-18 2023-07-31 Jesús Francisco Barberan Latorre Głowica, maszyna i sposób drukowania cyfrowego na podłożach
CA3160137A1 (en) 2019-11-05 2021-05-14 Bristol-Myers Squibb Company Methods of treatment with antibodies against bcma and cd3
EP4214233A1 (en) * 2020-09-16 2023-07-26 Amgen Inc. Methods for administering therapeutic doses of bispecific t-cell engaging molecules for the treatment of cancer
TW202233682A (zh) * 2020-11-10 2022-09-01 美商安進公司 用於投與ＢＣＭＡｘＣＤ３結合分子之方法

Also Published As

Publication number Publication date
WO2021094000A1 (en) 2021-05-20
RS65581B1 (sr) 2024-06-28
MA47888B1 (fr) 2024-10-31
EP4058148A1 (en) 2022-09-21
HUE066166T2 (hu) 2024-07-28
TW202118784A (zh) 2021-05-16
HRP20241281T1 (hr) 2024-12-06
ES2987783T3 (es) 2024-11-18
PT3819007T (pt) 2024-09-20
EP4424709A2 (en) 2024-09-04
FI3819007T3 (fi) 2024-09-25
AU2020381671A1 (en) 2022-03-31
ES2987070T3 (es) 2024-11-13
SMT202400165T1 (it) 2024-05-14
SI3819007T1 (sl) 2024-10-30
US20210139584A1 (en) 2021-05-13
HRP20240553T1 (hr) 2024-07-05
PT4058148T (pt) 2024-05-03
LT3819007T (lt) 2024-10-10
SMT202400373T1 (it) 2024-11-15
EP3819007B1 (en) 2024-07-10
PL4058148T3 (pl) 2024-09-16
PL3819007T3 (pl) 2024-11-18
DK4058148T5 (da) 2024-07-22
LT4058148T (lt) 2024-05-27
JP2025170264A (ja) 2025-11-18
CA3155069A1 (en) 2021-05-20
EP4058148B1 (en) 2024-03-13
EP3819007A1 (en) 2021-05-12
HUE068401T2 (hu) 2024-12-28
MX2022005628A (es) 2022-06-14
RS65943B1 (sr) 2024-10-31
DK4058148T3 (da) 2024-05-06
FI4058148T3 (fi) 2024-05-06
EP4424709A3 (en) 2024-12-11
SI4058148T1 (sl) 2024-06-28
JP2022554362A (ja) 2022-12-28

Similar Documents

Publication Publication Date Title
IL292753A (en) Compounds
EP3994692C0 (en) BINARY COMPUTING CELL IN MEMORY
EP3833739A4 (en) STRAIN OF AKKERMANSIA MUCINIPHILA
EP3973221C0 (de) Stop & go-molch
JP1719667S (ja) ディスペンサー
EP3919491C0 (en) AKT INHIBITOR
EP3930851A4 (en) COMBINATION THERAPIES
IL284807A (en) Antibodies specific to human nectin-2
EP4054636A4 (en) DOSAGE REGIME FOR ANTI-DLL3 AGENTS
EP3967649C0 (en) LIPID NANOPARTICLE
EP3975220A4 (en) Display panel
DK3819007T3 (da) Doseringsplan for anti-bcma-midler
EP3973348A4 (en) HEAD MOUNT DISPLAYS
EP3957391C0 (en) AGITATOR
EP3912517C0 (en) FRAME
EP4001694A4 (en) REDUCTION GEAR
EP3965638C0 (en) VAGINAL SPECULUM
EP3962498A4 (en) Combination therapies
DK3738452T3 (da) Fordamper
EP3682831C0 (en) CRYOGENIC APPLICATOR
PL4009942T3 (pl) Związek służący do leczenia skojarzonego
NO20170618A1 (no) Fortøyningsplate for oppdrettsanlegg
IL285046A (en) Anti-apicomplexan compositions
EP4054770A4 (en) DONOR
EP4051061C0 (en) ADJUSTABLE DOSING MEANS